S1085
Clinical – Upper GI
ESTRO 2026
chemoradiation, with Volumetric Arc Therapy (VMAT). The median radiation dose was 60 Gy (50- 70Gy/25-35 fractions/5-7 weeks). Results: The median age was 60 years (range 34–79), with a male-to-female ratio of 1.7:1. Median BMI was 20 kg/m2 (14.06 -31.5 kg/m2). The median gross tumour volume (GTV) volume was 24.3 cc (2-154 cc) and median craniocaudal extent of GTV was 5.7 cm (1.8- 10.5 cm). Concomitant chemotherapy was delivered in 94.6% with FOLFOX (Oxaliplatin,Leucovorin,5-FU) in 71% and TP (Pacliaxel+carboplatin) in 29%, with a median of 3 cycles. Consolidation chemotherapy was administered in 82% of eligible patients. Treatment completion rate was 89%, though 50% experienced interruptions. Elective nodal irradiation was performed in 97.4% of patients. Acute toxicities included dysphagia grade ≥ 2 in 56.7% and odynophagia in 32%. Treatment response evaluation 3months after treatment completion using endocscopy and positron emission tomography (PET) was done in 27 individuals and were included for survival analysis. There were 11 individuals for which treatment response evaluation was not done were excluded from further analysis (8 were still due for assessment and 3 were lost to follow-up). Among these 27 patients, complete response (CR) was achieved in 33.3% (n=9) , partial response (PR) in 33.3% (n=9), and progressive disease (PD) in 33.3%(n=9). Out
Conclusion: Definitive concurrent chemoradiation effectively preserves organs in cervical oesophageal SCC with acceptable toxicity and favourable local control. Disease progression remains concerning in advanced- stage tumours, but high compliance and VMAT-based techniques facilitate dose escalation. Prospective studies are needed to refine chemotherapy/immunotherapy regimens, optimize radiation dose, and identify predictive factors for survival. Keywords: Chemoradiation, VMAT Characterising Benign Radiation-Induced Strictures After Radical Radiotherapy forOesophageal Cancer: A Single-Centre Cohort Study Zainul Abedin Kapacee 1 , Ibrahim Elpum 2 , Bilal Mohammad Razzaq 1 , Charlotte Hewitt 1 , David Wilson 3 , Mohan Hingorani 4 , Paul Hatfield 1 , Chandran Nallathambi 1 , Eldho Joseph 1 , Simon Everett 2 , Mark Hull 2 , Rebecca Goody 1 1 Department of Clinical Oncology, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom. 2 Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, United Digital Poster 2452
of 27, 48% of patients experienced disease progression or death, predominantly distant
metastasis (53.8%). Median PFS (n=27) was 5.6 months and median OS (n=38) was 8.9 months. None of the patient (age, gender, ECOG), tumour (Stage, GTV volume) or the treatment characteristics (treatment interruptions) were significantly associated with PFS or OS.
Made with FlippingBook - Share PDF online